REFERENCES
Aartsma-Rus, A., & Krieg, A. M. (2017). FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.Nucleic Acid Therapeutics, 27(1), 1–3. https://doi.org/10.1089/nat.2016.0657 Bilandzic, M., Rainczuk, A., Green, E., Fairweather, N., Jobling, T. W., Plebanski, M., & Stephens, A. N. (2019). Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells. Cancers, 11(9). https://doi.org/10.3390/cancers11091228 Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q., & Krainer, A. R. (2003). ESEfinder: A web resource to identify exonic splicing enhancers.Nucleic Acids Research, 31(13), 3568–3571. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science,339(6121), 819–823. https://doi.org/10.1126/science.1231143 Ekker, S. C. (2006). Morphants: A New Systematic Vertebrate Functional Genomics Approach. Yeast (Chichester, England), 17(4), 302–306. https://doi.org/10.1002/1097-0061(200012)17:4<302::AID-YEA53>3.0.CO;2-# Geissler, R., Simkin, A., Floss, D., Patel, R., Fogarty, E. A., Scheller, J., & Grimson, A. (2016). A widespread sequence-specific mRNA decay pathway mediated by hnRNPs A1 and A2/B1. Genes & Development, 30(9), 1070–1085. https://doi.org/10.1101/gad.277392.116 Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., Qi, L. S., Kampmann, M., & Weissman, J. S. (2014). Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell,159(3), 647–661. https://doi.org/10.1016/j.cell.2014.09.029 Jain, N., Lin, H.-C., Morgan, C. E., Harris, M. E., & Tolbert, B. S. (2017). Rules of RNA specificity of hnRNP A1 revealed by global and quantitative analysis of its affinity distribution. Proceedings of the National Academy of Sciences of the United States of America,114(9), 2206–2211. https://doi.org/10.1073/pnas.1616371114 Jean-Philippe, J., Paz, S., & Caputi, M. (2013). hnRNP A1: The Swiss Army Knife of Gene Expression. International Journal of Molecular Sciences, 14(9), 18999–19024. https://doi.org/10.3390/ijms140918999 Kampmann, M. (2018). CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine. ACS Chemical Biology,13(2), 406–416. https://doi.org/10.1021/acschembio.7b00657 Kashima, T., Rao, N., David, C. J., & Manley, J. L. (2007). HnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing.Human Molecular Genetics, 16(24), 3149–3159. https://doi.org/10.1093/hmg/ddm276 Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014). Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nature Biotechnology,32(3), 267–273. https://doi.org/10.1038/nbt.2800 Lee, Y., & Rio, D. C. (2015). Mechanisms and Regulation of Alternative Pre-mRNA Splicing. Annual Review of Biochemistry, 84, 291–323. https://doi.org/10.1146/annurev-biochem-060614-034316 Mullenders, J., Fabius, A. W. M., Madiredjo, M., Bernards, R., & Beijersbergen, R. L. (2009). A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway. PLoS ONE, 4(3). https://doi.org/10.1371/journal.pone.0004798 Nogrady, B. (2019). The challenge of delivering RNA-interference therapeutics to their target cells. Nature, 574(7778), S8–S9. https://doi.org/10.1038/d41586-019-03071-9 Papafotiou, G., Paraskevopoulou, V., Vasilaki, E., Kanaki, Z., Paschalidis, N., & Klinakis, A. (2016). KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis.Nature Communications, 7(1), 11914. https://doi.org/10.1038/ncomms11914 Roberts, T. C., Langer, R., & Wood, M. J. A. (2020). Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery,19(10), 673–694. https://doi.org/10.1038/s41573-020-0075-7 Stein, C. A., & Castanotto, D. (2017). FDA-Approved Oligonucleotide Therapies in 2017. Molecular Therapy, 25(5), 1069–1075. https://doi.org/10.1016/j.ymthe.2017.03.023 Tycko, J., Wainberg, M., Marinov, G. K., Ursu, O., Hess, G. T., Ego, B. K., Aradhana, Li, A., Truong, A., Trevino, A. E., Spees, K., Yao, D., Kaplow, I. M., Greenside, P. G., Morgens, D. W., Phanstiel, D. H., Snyder, M. P., Bintu, L., Greenleaf, W. J., … Bassik, M. C. (2019). Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements. Nature Communications,10(1), 4063. https://doi.org/10.1038/s41467-019-11955-7 Zhu, L.-F., Hu, Y., Yang, C.-C., Xu, X.-H., Ning, T.-Y., Wang, Z.-L., Ye, J.-H., & Liu, L.-K. (2012). Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Laboratory Investigation, 92(5), 744–752. https://doi.org/10.1038/labinvest.2012.8